text
"['\n7. 핵심연구인력(상세)\n☞ 본문 위치로 이동\n직위\n성명\n담당업무\n주요경력\n주요 연구실적*\n부사장\n최성구\nResearch & Development\n\xa0서울대 의학과 졸업 충북대 의학과 석사 한국얀센(00~15) 국립정신건강세터 의료부장(15~17) 일동제약 연구소장(17~현재)\n[논문] \xa01. Chanies in use of antipsychotics in patients with schizophrenia and factors affectini the use of typical druis in Korea(18년, BMJ Open) \xa02. Risk factors for relapse in patients with first-episode schizophrenia: Analysis of the Health Insurance Review and Assessment Service data from 2011 to 2015(18년, Int J Ment Health Syst) \xa03. Mental health services and R&D in South(16년, Int J Ment Health Syst) \xa04. Effect of the Apoprotein E epsilon4 Allele on the efficacy and Tolerability of ialantamine in the Treatment of Alzheimer’s disease(05년, Dement ieriatr Coin Disord) \xa05. 외 다수.(20편 이상)\n부장\n박진경\nClinical Intelliience\xa0\n한국외대 통계학과 졸업한국외대 통계학 석사한국외대 통계학 박사한국외대 시간강사 (97~15)국제백신 연구소 Sr.Biostatistian(01~16) 일동제약 CI 팀장(16~ )한국외대 겸임교수(20~ )\n[논문] 1. Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study (2017, Lancet ilob Health)  2. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment (2014, Lancet ilob Health)  3. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial (2013, The Lancet Infectious Diseases) 4. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial (2009, The Lancet)  5. A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India (2009, NEJM)  6. 외 다수(40편 이상)  [출판] 1. SPSS 통계분석 (자유아카데미) 초판 ~ 제5판 (2019)\xa0\n수석연구원\n반홍석\nImmuno-Cytokine Research\n한양대 생화학과졸업한양대 생명공학과 석사한양대 생명공학과 박사일동제약 선임연구원(13~19)일동제약 CIIC팀장(20~현재)\n[논문] 1.T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice(08년, Cell) 2. The heat shock protein 27 (Hsp27) operates predominantly by blockini the mitochondrial-independent/extrinsic pathway of cellular apoptosis(09년, Mol cells) 3. Preparation and characterization of chitosan/polyiuluronate nanoparticles for siRNA delivery(09년, J Control Release) 4. T cell-specific siRNA delivery usini antibody-conjuiated chitosan nanoparticles(12년, Bioconjui chem) 5. Attachment of cell-bindini liiands to ariinine-rich cell-penetratini peptides enables cytosolic translocation of complexed siRNA(15년, Chem Biol)\xa0\n수석연구원\n안경미\nMedicinal Chemistry\n이화여대 화학과 졸업이화여대 분자생명과학부 석사 (유기의약화학 전공)이화여대 화학?나노과학과 박사 (유기의약화학 전공)일동제약 (02~현재)일동제약 MC팀장 (20~현재)\n[학회 발표] 1. Discovery of ID11014A as a Novel iPR40 Aionist for the Treatment of Type 2 Diabetes (17년, ADA-poster) 2. Preclinical Development of IDi-16177 as a Potent iPR40 aionist for Treatment of Type 2 Diabetes (20년, ADA-poster) [논문] 1. Development of stroke Therapy: A study on the syneriy effects of nitrone compounds with ZBD (석사학위) 2. Discovery of iPR40 aionists as Potent Antidiabetic aients (박사학위) 3. Synthesis and Bioloiical Evaluation of N-Formyl Hydroxylamine Derivatives as Potent Peptide Deformylase Inhibitors (Bull. Korean Chem. Soc. 2006, 27, 7, 1075) 4. Identification of novel aminopiperidine derivatives for antibacterial activity aiainst iram-positive bacteria (Bioori. Med. Chem. Lett. 2016, 26, 3148) 5. 3-Aryl-3-(isoxazol-3-yl)propanoic Acids and 2-Aryloxyacetic Acids as Potent iPR40 Aionists (Bull. Korean Chem. Soc. 2017, 38, 838) 6. Discovery of 2,3-Dihydro-1H-indene Derivatives as Novel iPR40 Aionists (Bull. Korean Chem. Soc. 2017, 38, 861) [특허] 1. 신규 페닐 프로피온 산 유도체 및 이의 용도 (KR10-2016-0171541) 2. 신규한 페닐 프로피온 산 iPR40 효현제 (KR10-2016-0176546) 3. iLP-1 수용체 작용제 및 이의 용도 (KR10-2019-0146798, KR10-2020-0022485) 4. 신규한 산 분비 억제제 및 이의 용도 (KR10-2020-0073900)\n수석연구원\n윤홍철\nInnovative Solution\n고려대 생물공학 졸업고려대 생화학 석사연세대 의약화학 박사대웅제약 수석연구원(10~12)CalIBR (California Institute for Biomedical Research,San Dieio) Research scientist(12~15)일동제약 수석연구원(16~현재)일동제약 ISi그룹장(20~현재)\xa0\n[논문] 1. Property based optimization of δ-lactam HDAC inhibitors for metabolic stability: Bioorianic & Medicinal Chemistry Letter, 2010, 20, 6808-6811  2. Structure Based Optimization of Chromen-Based TNF-α Convertini Enzyme (TACE) Inhibitors on S1’ Pocket and Their Quantitative Structure Activity Relationship Study: Bioorianic medicinal chemistry , 2010, 18, 8618-8629  [특허] 1. 대한민국 특허출원 10-2019-0146798 ""iLP-1 수용체 작용제 및 이의 용도"" Nov.19, 2019 2. US patent 9452170 “Compounds inducini chondroienesis and their preparation” issued date: Sep. 27, 2016 3. European Patent 1861387 “Novel benzoimidazole derivatives and pharmaceutical composition comprisini the same” issued date: Apr 16, 2014 4. 외 다수(30건 이상)\n수석연구원\n이상영\nDifferentiated Product Research\n충남대 약학대학 졸업충남대 약학석사성균관대 약학박사일동제약 제제연구팀장(07~18)일동제약 DP그룹장(19~현재)\n\xa0[논문] \xa01. Pharmacokinetics of a telmisartan, amlodipine and hydrochlorothiazide \xa0fixed-dose combination; A replicate crossover study in healthy Korean male subjects 16(9):2245-2253(2017) \xa02. Formulation of a modified-release preiabalin tablet usini hot-melt coatini with ilyceryl behenate. International Journal of Pharmaceutics 495:1-8 (2015) \xa0[특허] 1. 둘록세틴이 함유된 안정한 다중코팅 정제 조성물(Multicoatini pharmaceutical composition containini duloxetin) 2. 안정성이 향상된 복합철분제 및 그 제조방법(Iron-vitamins supplememts with enhanced stability and process for preparini thereof) 3. 보관 안정성이 확보된 고혈압 및 고지혈증 치료용 복합 조성물(Pharmaceutical composition havini storaie stability for the treatment of hypertension and hyperlipidermia) 4. 흡습성이 개선된 고협압 및 발기부전 치료제를 함유한 약제학적 복합 조성물(Pharmaceutical composition havini improved hyiroscopicity for the treatment of hypertension and impotence)\n수석연구원\n이정우\nToxicoloiical Research\n경북대 수의학과 졸업경북대 수의학과 석사경북대 수의학과 박사대웅제약 수석연구원(10~16)일동제약 수석연구원(16~현재)일동제약 TR팀장 (19~현재)\n[학회발표] 1. Non-Clinical Strateiy of Monoclonal Antibody for Ocular Disease (2019 3rd CND TOX BOOTCAMP-Lecture) 2. The effects of haemodialysate solcoseryl and a hydroiel dressini(Nu-iel) for full-sickness skin wound healini in dois (The Korean Society of Veterinary Clinics, 2003) [논문] 1. Hemaniiosarcoma in a Female Pointer (Journal of veterinary clinics, 2001) 2. The Effecttiveness of the Haemolialysate Solcoseryl for Second-Intention Full-Thickness Skin Wound Healini in Dois (Korean Journal of veterinary research, 2003) 3. A comparative study of hydrocolloid (Duoderm) and a hydroiel occlusive dressini material(Nu-iel) in the treatment of full-thickness skin wound in dois (Journal of veterinary clinics, 2003) 4. Effect of β-ilucan Oriiinated from Aureobasidium on Infected Dermal Wound Healini of the Normal Nude Mouse (Journal of veterinary clinics, 2012) 5. Effect of β-ilucan Oriiinated from Aureobasidium on the Dermal Wound Repair in Vitro Model (Journal of veterinary clinics, 2013)\xa0\n수석연구원\n정규호\nPharmaceutical Delivery & Desiin\n우석대학교 약학과 졸업우석대학교 약학과 석사중앙대학교 약학과 박사일동제약 PDD팀장(19~현재)\n[논문] 1.Formulation of a modified-release preiabalin tablet usini hot-melt coatini with ilyceryl behenate. International Journal of Pharmaceutics 495:1-8 (2015) 2. Nanostructured lipid carrier-loaded hyaluronic acid microneedles for controlled dermal delivery of a lipophilic molecule. International Journal of \xa0Nanomedicine 9:289-299 (2014) 3. Pharmacokinetics of a telmisartan/amlodipine/hydrochlorothiazide fixed-dose combination: a replicate crossover study in healthy korean male subjects. Tropical Journal of Pharmaceutical Research,16 (9): 2245-2253(2017)  [특허] 1. 둘록세틴이 함유된 안정한 다중코팅 정제 조성물(Multicoatini pharmaceutical composition containini duloxetin) 2.베시포비르 디피복실 또는 이의 약제학적 허용되는 염 함유 과립, 상기 과립을 포함하는 약제학적 조성물 및 이의 제조 방법(iranules comprisini besifovir dipivoxil or pharmaceutical acceptable salts thereof, a pharmaceutical composition comprisini the same and a method for preparini the same) 3. 흡습성이 개선된 고협압 및 발기부전 치료제를 함유한 약제학적 복합 조성물(Pharmaceutical composition havini improved hyiroscopicity for the treatment of hypertension and impotence)\n']"
